Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Diabetes, Obesity & Metabolism|November 7, 2019
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetesAmalia Gastaldelli, Enrico Repetto, Cristian Guja, et al.
Postgraduate Medicine|June 11, 2013
Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trialsMichael Grimm, Jenny Han, Carole Weaver, et al.
Frontiers in Immunology|June 18, 2025
Case Report: Unilateral relapsing primary central nervous system vasculitis-expanding the phenotypeTurlough Montague, Jenny Han, Emily Cheung, et al.
Diabetes Care|October 27, 2004
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesJohn B Buse, Robert R Henry, Jenny Han, et al.
Hemoglobin|December 23, 2011
Secondary mutation (c.94_95delAG) in a -α3.7 allele associated with Hb H disease in two unrelated African American individuals homozygous for the -α(3.7) deletion (-α3.7/-α3.7T)Po Zhao, Arlene M Buller-Burckle, Mei Peng, et al.
Diabetes Care|April 28, 2005
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesRalph A DeFronzo, Robert E Ratner, Jenny Han, et al.
Clinical Therapeutics|May 22, 2012
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic reviewVanita R Aroda, Robert R Henry, Jenny Han, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 3, 2012
A novel mRNA binding protein complex promotes localized plasminogen activator inhibitor-1 accumulation at the myoendothelial junctionKatherine R Heberlein, Jenny Han, Adam C Straub, et al.
Journal of Drugs in Dermatology : JDD|August 9, 2023
Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne VulgarisLawrence F Eichenfield, Adelaide A Hebert, Linda Stein Gold, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trialMichaela Diamant, Luc Van Gaal, Bruno Guerci, et al.
Pageof 6